Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Danesi

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsA Di Paolo, R Danesi, A Falcone, et al.
Experimental Eye Research|September 12, 1998
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularizationU Benelli, G Bocci, R Danesi, et al.
Bone Marrow Transplantation|March 7, 2003
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding studyC Bengala, R Danesi, V Guarneri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patientsG Bocci, R Danesi, A D Di Paolo, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1996
Clinical and experimental evidence of inhibition of testosterone production by suraminR Danesi, R V La Rocca, M R Cooper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)C Bengala, I Pazzagli, F Innocenti, et al.
ESMO Open|February 4, 2021
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor BoardsR Danesi, S Fogli, S Indraccolo, et al.
International Journal of Laboratory Hematology|July 21, 2015
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasmsG Fontanelli, C Baratè, E Ciabatti, et al.
British Journal of Cancer|April 30, 2008
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinibG Bocci, A Falcone, A Fioravanti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancerP F Conte, E Baldini, A Gennari, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsA Di Paolo, R Danesi, A Falcone, et al.
Experimental Eye Research|September 12, 1998
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularizationU Benelli, G Bocci, R Danesi, et al.
Bone Marrow Transplantation|March 7, 2003
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding studyC Bengala, R Danesi, V Guarneri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patientsG Bocci, R Danesi, A D Di Paolo, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1996
Clinical and experimental evidence of inhibition of testosterone production by suraminR Danesi, R V La Rocca, M R Cooper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)C Bengala, I Pazzagli, F Innocenti, et al.
ESMO Open|February 4, 2021
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor BoardsR Danesi, S Fogli, S Indraccolo, et al.
International Journal of Laboratory Hematology|July 21, 2015
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasmsG Fontanelli, C Baratè, E Ciabatti, et al.
British Journal of Cancer|April 30, 2008
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinibG Bocci, A Falcone, A Fioravanti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancerP F Conte, E Baldini, A Gennari, et al.
Pageof 16